Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nanoparticle drug aims to wake up immune system against tumors

NCT ID NCT07605962

Recruiting now Disease control Sponsor: United Immunity, co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the safest dose, then see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UI-102 (a nanoparticle that activates the immune system to attack tumors)
What this could lead to
If successful, this could lead to a new immunotherapy option for people with advanced solid tumors that have not responded to standard treatments.
What could go wrong
This is an early phase 1/2 trial with a small number of participants, so safety and effectiveness are not yet proven. Immune activation can also cause side effects like flu-like symptoms or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • NEXT Oncology

    RECRUITING

    Dallas, Texas, 75039, United States

  • NEXT Oncology

    RECRUITING

    Houston, Texas, 77054, United States

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.